IDEAYA Biosciences, Inc.
No SEC Form 4 filings for $IDYA in the last 30 days.
See all $IDYA insider activity →Ultragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
IDEAYA Biosciences (IDYA) and Genentech (part of Roche) will collaborate on a clinical trial to evaluate IDE892, IDEAYA's PRMT5 inhibitor, in combination with Genentech's KRAS G12D inhibitor, RG6620, for pancreatic cancer patients with MTAP deletions and KRAS G12D mutations. Genentech will sponsor the trial, and IDEAYA will supply IDE892. IDE892 has shown potential best-in-class properties, including selective binding and favorable drug-like properties. The companies will retain commercial right
IDEAYA Biosciences, Inc. (IDYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update • Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway
Over the past 7 days, alphai's AI scored 1 news story mentioning IDYA (IDEAYA Biosciences, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent IDYA coverage spans financial news, technology and regulation.
Collaboration with a Roche unit adds credibility and potential future revenue.
The partnership could boost IDEAYA's pipeline value and attract investor interest, but clinical outcomes remain uncertain.
Positive registrational Phase 2/3 efficacy results and an active RTOR NDA filing increase probability of regulatory progress, supporting a bullish risk/reward into 2026 catalysts.
Inducement option grants are typically modest for near-term valuation, but they confirm ongoing hiring and provide a clear equity compensation datapoint.
Initiating Part 2 monotherapy expansion is a tangible clinical-program milestone that can improve perceived probability of success, but it is not yet efficacy or safety readout.
alphai scores every news story that mentions IDYA with an AI model for sentiment and relevance, and aggregates insider trades from IDEAYA Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ultragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
3 min readIDEAYA Biosciences (IDYA) and Genentech (part of Roche) will collaborate on a clinical trial to evaluate IDE892, IDEAYA's PRMT5 inhibitor, in combination with Genentech's KRAS G12D inhibitor, RG6620, for pancreatic cancer patients with MTAP deletions and KRAS G12D mutations. Genentech will sponsor the trial, and IDEAYA will supply IDE892. IDE892 has shown potential best-in-class properties, including selective binding and favorable drug-like properties. The companies will retain commercial right
2 min readIDEAYA Biosciences, Inc. (IDYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update • Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway
6 min readSOUTH SAN FRANCISCO, Calif., July 31, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on July 30, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 260,200 shares of the Company's common stock to fourteen newly hired employees.
1 min readIDEAYA Biosciences (NASDAQ: IDYA) said it initiated Part 2 monotherapy expansion in its Phase 1/2 trial of IDE892, a PRMT5 inhibitor for MTAP-deleted PDAC and NSCLC. The company reported projected efficacious target exposures and that the MTD has not been reached. IDE892 and IDE397 combination escalation continues, and a Roche RG6505 combo is in collaboration.
2 min readIDEAYA Biosciences (Nasdaq: IDYA) said it will present three ESMO 2026 abstracts in Madrid on darovasertib and IDE849. Darovasertib data will cover Phase 2/3 OptimUM-02 (HLA*A2:01-negative metastatic uveal melanoma), Phase 2 OptimUM-01 (HLA*A2:01-positive), and Phase 2 OptimUM-09 (neoadjuvant). Partner Hengrui will present long-term Phase 1 IDE849 (SHR-4849) results in relapsed SCLC and NECs.
2 min readIDEAYA Biosciences, Inc. (IDYA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001676725 0001676725 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16,
3 min readThe article is largely promotional and does not provide verifiable details about Ideaya Biosciences or a Roche partnership. It claims IDYA formed a clinical partnership with Roche for an IDE892 efficacy study, but offers no study design, timeline, or financial figures. The rest focuses on AI market commentary and newsletter subscription offers.
6 min readBiotech stocks rose Monday as investors reacted to clinical and regulatory updates. Tango Therapeutics (TNGX) jumped 52.97% after initial Phase 1/2 pancreatic cancer data showed 90% 6-month PFS; Alvotech (ALVO) gained 19.77% as the FDA accepted its Entyvio interchangeable biosimilar AVT16; Zevra (ZVRA) rose 13.95% on an Orange Book listing for MIPLYFFA.
7 min readLifeSci Capital has reiterated its Buy rating on IDEAYA Biosciences (IDYA.US), maintaining a target price of $62. This indicates a positive outlook on the company's future stock performance and financial health.
2 min read
